Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

MediciNova, Inc. - Common Stock (NQ:MNOV)

1.460 +0.220 (+17.74%)
Streaming Delayed Price Updated: 4:00 PM EDT, Jul 25, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 199,511
Open 1.310
Bid (Size) 1.480 (5)
Ask (Size) 1.550 (4)
Prev. Close 1.240
Today's Range 1.310 - 1.460
52wk Range 1.120 - 2.550
Shares Outstanding 49,046,246
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
MediciNova Provides Enrollment Update for Ongoing ALS and Hypertriglyceridemia Clinical Trials
MN-166 COMBAT ALS trial down to single digit required enrollment while MN-001 hypertriglyceridemia trial in type 2 diabetes patients requires final two patients 
From MediciNova, Inc.
Via GlobeNewswire
MediciNova To Participate in D. Boral’s Capital Global Conference on May 14, 2025
From MediciNova, Inc.
Via GlobeNewswire

Performance

YTD
-31.5%
-31.5%
1 Month
+12.3%
+12.3%
3 Month
-6.4%
-6.4%
6 Month
-24.4%
-24.4%
1 Year
+11.5%
+11.5%

More News

Read More
First Patient Enrolled in NIH-Funded Expanded Access Program (EAP) Trial to Evaluate MN-166 in Amyotrophic Lateral Sclerosis (ALS) Patients
From MediciNova, Inc.
Via GlobeNewswire
MediciNova Presents Study Update and Interim Analysis of Phase 2/3 Clinical Trial of MN-166 (ibudilast) in ALS (COMBAT-ALS Clinical Trial) at the 35th International Symposium on ALS/MND
From MediciNova, Inc.
Via GlobeNewswire
This Autodesk Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Monday
Via Benzinga
MediciNova CEO Yuichi Iwaki Provides Corporate Update in Letter to Stockholders
From MediciNova, Inc.
Via GlobeNewswire
MediciNova Receives Notice of Allowance from United States Patent and Trademark Office for New Patent Covering MN-001 for Triglyceride Synthesis in the Liver
From MediciNova, Inc.
Via GlobeNewswire
MediciNova Given Notice of Monetary Damages Due Under Patent Settlement of Sanofi-Novartis
From MediciNova, Inc.
Via GlobeNewswire
12 Health Care Stocks Moving In Thursday's Pre-Market Session
Via Benzinga
MediciNova Announces Update of Phase 2/3 Clinical Trial of MN-166 (ibudilast) in ALS patients (COMBAT-ALS) at the 2024 Annual NEALS Meeting (Northeast Amyotrophic Lateral Sclerosis Consortium)
From MediciNova, Inc.
Via GlobeNewswire
12 Health Care Stocks Moving In Friday's Intraday Session
Via Benzinga
MediciNova to Support NIH-Funded Expanded Access Clinical Trial to Evaluate MN166 (ibudilast) in Amyotrophic Lateral Sclerosis (ALS)
From MediciNova, Inc.
Via GlobeNewswire
MediciNova Announces Abstract Regarding MN-166 (ibudilast) in COMBAT-ALS Clinical Trial Accepted for Poster Presentation at the 35th International Symposium on ALS / MND
From MediciNova, Inc.
Via GlobeNewswire
MediciNova Announces Acceptance of Abstract Regarding MN-166 (ibudilast) in COMBAT-ALS Clinical Trial for Presentation at the 2024 Annual NEALS (Northeast Amyotrophic Lateral Sclerosis Consortium) Meeting
From MediciNova, Inc.
Via GlobeNewswire
MediciNova Receives Notice of Allowance from United States Patent and Trademark Office for New Patent Covering MN-166 (ibudilast) for the Post-COVID Condition
From MediciNova, Inc.
Via GlobeNewswire
Why Recursion Pharmaceuticals Shares Are Trading Lower By Around 10%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
Via Benzinga
MNOV Stock Earnings: MediciNova Beats EPS for Q2 2024
Via InvestorPlace
MediciNova Chief Business Officer David H. Crean, Ph.D. Assumes Communications Role Overseeing Investor Engagement and Public Relations
From MediciNova, Inc.
Via GlobeNewswire
MediciNova Receives Notice of Allowance for New Patent Covering MN-166 (ibudilast) for the Prevention of Metastasis of Various Solid Cancer
From MediciNova, Inc.
Via GlobeNewswire
MediciNova Announces Data from Phase 1b/2a Clinical Trial of MN-166 (ibudilast) in Glioblastoma Patients at the American Society of Clinical Oncology (ASCO) Annual Meeting 2024
From MediciNova, Inc.
Via GlobeNewswire
MediciNova Announces Two Poster Presentations at the 92nd EAS Congress 2024, the Annual Meeting of the European Atherosclerosis Society Regarding the Use of MN-001 (Tipelukast) for Cardiometabolic Conditions
From MediciNova, Inc.
Via GlobeNewswire
MediciNova Receives Notice of Allowance for New Patent Covering MN-166 (ibudilast) for the Prevention of Metastasis of Eye Cancer
From MediciNova, Inc.
Via GlobeNewswire
MediciNova Receives Notice of Allowance for New Patent Covering MN-166 (ibudilast) for the Treatment of Chlorine-Induced Acute Respiratory Distress Syndrome
From MediciNova, Inc.
Via GlobeNewswire
MNOV Stock Earnings: MediciNova Misses EPS for Q1 2024
Via InvestorPlace
MediciNova Receives Issue Notification for New Patent Covering Extended-Release Formulations of MN-166 (ibudilast)
From MediciNova, Inc.
Via GlobeNewswire

Frequently Asked Questions

Is MediciNova, Inc. - Common Stock publicly traded?
Yes, MediciNova, Inc. - Common Stock is publicly traded.
What exchange does MediciNova, Inc. - Common Stock trade on?
MediciNova, Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for MediciNova, Inc. - Common Stock?
The ticker symbol for MediciNova, Inc. - Common Stock is MNOV on the Nasdaq Stock Market
What is the current price of MediciNova, Inc. - Common Stock?
The current price of MediciNova, Inc. - Common Stock is 1.460
When was MediciNova, Inc. - Common Stock last traded?
The last trade of MediciNova, Inc. - Common Stock was at 07/25/25 04:00 PM ET
What is the market capitalization of MediciNova, Inc. - Common Stock?
The market capitalization of MediciNova, Inc. - Common Stock is 71.61M
How many shares of MediciNova, Inc. - Common Stock are outstanding?
MediciNova, Inc. - Common Stock has 72M shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.